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A review of publications relating to significant advances in
the specialty of Obstetrics and Gynaecology over the past four
years will be discussed: topics reviewed will have an important
impact on reducing maternal/fetal morbidity and mortality and
should improve on woman’s health care.
Prevention of  Preterm Delivery
Preterm labour is the most common cause of fetal morbidity
and perinatal mortality. Women who have had a spontaneous
preterm delivery will be at an increased risk of having a preterm
delivery in subsequent pregnancies and among the
complications related to prematurity, there are respiratory
distress syndrome, necrotising enterocolitis and intraventricular
haemorrhage.
Progesterone applied as a weekly intramuscular injection
or as daily vaginal pessaries, was utilised in two double-blind,
placebo-controlled trials involving pregnant women with a
documented history of spontaneous preterm delivery.  In one
study, treatment with 17 alpha-hydroxyprogesterone caproate
(17P)1 intramuscularly on a weekly basis, was initiated at 16 to
20 weeks of gestation and continued till 36 weeks of gestation.
The primary outcome was preterm delivery before 37 weeks of
gestation.
Treatment with 17P significantly reduced the risk of delivery
at less than 35 weeks of gestation (incidence, 20.6 % vs. 30.7 %;
RR, 0.67, 95 % CI, 0.48 to 0.93), and delivery at less than 32
weeks of gestation (11.4 % vs. 19.6 %; RR, 0.58, 95 % CI, 0.37 to
0.91. There were also significantly lower rates of necrotizing
enterocolitis, intraventricular hemorrhage and need for
supplemental oxygen in the progesterone treated group.
In another study utilising daily progesterone pessaries
(100mg), between 24 and 34 weeks gestation preterm delivery
was noted in 2.8% in the progesterone group (72 patients) and
18.6% in the placebo group (74 patients) giving a reduction of
85%.2  Both studies show great promise in the application of
progesterone as a safe prevention against preterm labour.
Treatment of Menorrhagia
Twenty years ago, hysterectomy was the mainstay of
treatment for menorrhagia, with over 60% of patients referred
for this symptom being treated with this surgical procedure.
The levonorgestrel intrauterine system (LNG-IUS, Mirena) has
been shown to be highly effective in reducing menstrual blood
loss by up to 80% and consequently a significant reduction in
the numbers of patients proceeding to hysterectomy has been
noted.
Over the years 1989-1990 till 2002-2003, NHS hospital
episode statistics were examined for hysterectomy rates,
compiled from data submitted by over 300 NHS trusts in the
U.K.3  From 1989-1990 to 1994-1995 an average of 23,056
hysterectomies a year were performed for menorrhagia in the
U.K. In 2002-2003, 8,332 hysterectomies and 4,921
endometrial ablations were performed, representing a reduction
of 64% in the number of hysterectomies and a reduction of 43%
(13 253 v 23 284) in the total number of operations for
menorrhagia compared with 1989-90.  Medical treatments for
menorrhagia are increasingly being applied with success
reducing the need to resort to surgical intervention.
Early Diagnosis and New Chemotherapy
Regimen for Women with Ovarian Cancer
Approximately 25,000 new cases of ovarian cancer are
diagnosed in the United States each year.  This disease is often
diagnosed at a late stage when the disease has led to ascites and
abdominal metastasis and the mortality within five years of
diagnosis is 70%.
Early detection of ovarian cancer is urgently needed in view
of the lethal nature of this disease. The rationale behind a study
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on proteomic spectra relies on the fact that pathological
changes within an organ might be reflected in proteomic
patterns in serum, as detected by mass spectrometry. A
bioinformatics tool was developed to identify proteomic
patterns in serum that distinguish neoplastic from non-
neoplastic disease within the ovary.  A pilot study of proteomic
spectra derived from analysis of serum from 50 controls and
50 patients with ovarian cancer were analysed and a proteomic
pattern that completely discriminated cancer from non-cancer
was discovered. The same pattern was applied to an
independent group of 116 blinded serum samples: 50 from
women with ovarian cancer, and 66 from controls. The
proteomic spectral pattern correctly identified all 50 ovarian
cancer cases in the blinded group, including all 18 stage I cases.
Of the 66 cases of non-malignant disease, 63 were recognised
as not cancer. This result yielded a sensitivity of 100% (95% CI
0.93 to 1.00), specificity of 95% (0.87 to 0.99), and positive
predictive value of 94% (0.84 to 0.99).  A large prospective
population-based study is underway of proteomic pattern
technology as a screening tool for all stages of ovarian cancer
in high-risk and general populations.4
Ovarian cancer Treatment
Chemotherapy with carboplatin, a platinum-based drug,
and a taxane-based drug (paclitaxel) is considered to be the
standard care for the initial treatment of ovarian cancer.
However more than a third of patients given standard
treatment suffer from severe peripheral neuropathy. A new
taxane-based chemotherapy using docetaxel with elevated anti-
tumor activity on ovarian cancer and a favourable side-effect
profile has been administered in a new trial.  In this recent
phase III trial, the combination of docetaxel and carboplatin
chemotherapy was compared with the standard treatment of
pactlitaxel and carboplatin as first-line treatment for women
diagnosed with stage Ic-IV epithelial ovarian or primary
peritoneal cancer.  The overall survival rates at two years were
similar to standard therapy but the nerve fibre toxicity was
lower in the docetaxel-carboplatin group (11% versus 30%).5
Safety and Usefulness of Ultrasound
in Obstetrics
Since 1990, an Australian group randomised 3000
pregnancies to a single mid-trimester ultrasound or a series of
five ultrasounds, to see if routine or serial ultrasonographic
investigations made a difference in perinatal or long-term
outcome. This group has published their findings of children
who are now eight years of age. This is the fifth assessment of
these children since birth, and the parameters measured
included speech, language, behaviour and neurological
development. Both groups of children had similar scores for
the parameters measured and were doing equally well at junior
school level.6  This longitudinal study confirms the long-term
safety of serial obstetric ultrasound which is frequently being
applied as a form of screening and monitoring tool.
 The usefulness of serial growth and Doppler ultrasound
assessments has been shown in several articles as the following
paper demonstrates.  Longitudinal changes in the middle
cerebral artery blood flow in severely growth restricted fetuses
were serially examined by Doppler. Outcome measures included
indication for delivery, umbilical venous pH and admission to
and length of stay in neonatal intensive care.
The middle cerebral artery pulsatility index showed rapid
and sharp changes between examinations in those severely
growth restricted fetuses which required delivery before 34
weeks. The middle cerebral artery pulsatility index
demonstrated greater variation in those fetuses with cord pHs
of less than 7.25. The length of stay in neonatal intensive care
decreased with increasing gestational age and birth weight.7
Menopause
The Woman’s Health Initiative (WHI) Study
The Woman’s Health Initiative (WHI) was a prospective
placebo/controlled study of sex hormones used as replacement
therapy in women during menopause. It was designed to study
whether placing a postmenopausal woman on HRT is beneficial
to their long and short term cardiovascular health, bearing in
mind that cardiovascular disease is the most common cause of
death in post-menopausal women.
The mean age of women on entering the study was 63 years
(on average 15 years post-menopausal). The dose of oestrogen
and progesterone given to the average 63-68 year old woman
in the study was the same as that usually given to their 40-50
year old counterparts in the trial and roughly twice the
physiological dose for the older-age group woman.
Oestrogens have a beneficial effect on the lipid profile, but
this may be opposed by the progestins component in HRT.
Amongst the progestins with such a deleterious effect is
medroxyprogesterone acetate (MPA) which was used in the WHI
study.
The progestin used and the age of the women recruited may
in part explain the results obtained. Estimated hazard ratios
(95% confidence intervals [CIs]) were as follows: coronary heart
disease, 1.29 (1.02-1.63); breast cancer, 1.26 (1.00-1.29); stroke,
1.41 (1.07-1.85); PE, 2.13 (1.39-3.25); colorectal cancer, 0.63
(0.43-0.92); endometrial cancer, 0.83 (0.47-1.47); hip fracture,
0.66 (0.45-0.98).8  The deleterious effect of the progestin used
became more apparent by its absence in the estrogen only arm
of the WHI study.  Estimated hazard ratios (95% CI) were:
coronary heart disease 0.91 (0.75-1.12); breast cancer, 0.77 (0.59-
1.01); stroke, 1.39 (1.10-1.77); PE, 1.34 (0.87-2.06); colorectal
cancer, 1.08 (0.75-1.55); and hip fracture, 0.61 (0.41-0.91).9
The WHI study was a study of HRT on relatively old post
menopausal women, a large proportion of whom were
overweight, had cardiac risk factors and/or a family history of
breast cancer. Post/perimenopausal women normally requiring
HRT are at least 10-15 years younger than the women recruited
in the WHI study.10
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Million Woman Study
The Million Woman Study was carried out over five years
up to early 2001. NHS breast screening centres participating
included a study questionnaire with a letter of invitation “to
assess the risk for breast cancer” sent two to six weeks before
mammography. The questionnaire contained questions on
various factors, including use of HRT (what, when, for how long)
and menstrual history. There were 1,084,100 women in the
study and at recruitment the average age was 56 years. Past
use, even for less than a year, was associated with no increased
risk. Over 4.1 years of HRT use there was one extra breast cancer
death for every 16,000 women currently using HRT. Five extra
cases of breast cancer were identified among users of oestrogen-
only HRT and 19 among users of oestrogen-progestagen
combinations for every thousand postmenopausal women who
begin 10 years of HRT use at age 50.11
The million women study has however received severe
criticism regarding the basic methodology utilised to implement
the study especially in view of strong biases in recruitment.
Nurses Health Study
The Nurses Health Study followed over 100,000 women for
24 years and was set up to examine a number of parameters
including the relationship between exercise, body mass index
(BMI) and risk of death. In this study, the effects of obesity were
related to the risk of death, which risk increased, regardless of
the level of physical activity. Although higher levels of physical
activity appeared to be beneficial at all levels of adiposity, it did
not eliminate the higher risk of death associated with it. Even
modest weight gain during adulthood, independent of physical
activity, was associated with a higher risk of death.
Conclusions from the study show that, 31 percent  of all
premature deaths, 59 percent of deaths from cardiovascular
disease, and 21 percent of deaths from cancer among
nonsmoking women, could be accounted for from the excessive
weight (defined as a body-mass index of 25 or higher) and
physical inactivity (less than 3.5 hours of exercise per week).
Both increased adiposity and reduced physical activity are strong
and independent predictors of death.12
From the Nurses Study, evidence suggested that impaired
intrauterine fetal growth is associated with cardiovascular
disease later on in life. Risk factors for cardiovascular disease
such as diabetes and hypertension showed an increased
prevalence later on in adult life, in individuals who had a fetal
history of growth restriction.12
Venous Thromboembolism in Pregnancy
Venous thromboembolism (VTE) is a common cause of
maternal morbidity and mortality. It can be reduced by either
prophylaxis and/or treatment in women at increased risk or by
extensively investigating women who present with symptoms
that raise a suspicion of clinical VTE.  Venous thromboembolism
is commoner in pregnant women suffering from thrombophilia.
Besides VTE, pregnancy complications such as placental
infarction, including miscarriage, intrauterine growth
retardation, preeclampsia, abruption, and intrauterine death
may arise.
Often in combination with aspirin, anticoagulant therapy
is administered for the prevention of pregnancy loss in women
with anitiphospholipid (APLAs) syndrome or thrombophilia
and previous pregnancy losses.  Patients with APLAs and no
prior VTE or pregnancy loss should be considered to have an
increased risk for the development of venous thrombosis and
pregnancy loss. One of the four approaches that can be
implemented include mini-dose heparin, prophylactic low
molecular weight heparin (LMWH), or low-dose aspirin, 80
to 325 mg daily.  The indication for active prophylaxis is
stronger in antithrombin III -deficient women than the other
thrombophilias.
For multiple (more than two) episodes of VTE, and/or
women receiving long-term anticoagulation therapy (eg, single
episode of VTE, either idiopathic or associated with
thrombophilia), adjusted-dose unfractionated heparin or
either prophylactic or adjusted-dose LMWH, followed by
resumption of long-term anticoagulation therapy postpartum
is indicated.14
Postmenopausal Osteoporosis
The American College of Obstetricians and Gynaecologists
has recognized that postmenopausal osteoporosis is the
epidemic of the future. It has published clear guidelines as to
the role of  gynaecologists in the prevention and therapy of
this condition.15
A bone density measurement one standard deviation below
normal increases the risk that a post-menopausal woman will
sustain a fracture by 50%. Other features associated with
fracture risk are age, female sex, small body frame, and white
race. The National Osteoporosis Risk assessment study
however indicated that 50% of postmenopausal women who
sustained a fracture were osteopaenic rather than osteoporotic
suggesting that nondensity variables may be also relevant.16
As regards vertebral fractures which affect 25-40% of the
postmenopausal population a possible nondensity variable
may be the shock-absorbing intervertebral discs.17
It has been shown that HRT will help to preserve the bone
mass. The WHI study showed this even in those women who
started  HRT well after the menopause. As primary prevention,
it lowers hip fracture rates by about a third (RR 0.67).8
Selective oestrogen receptor modulators (SERM) which will
reduce bone resorption as well as reducing the risk of breast
cancer are being investigated. At present raloxifene is the only
SERM registered for osteoporosis prevention. Vitamin D
(800iu daily) supplementation and an intake of 800-1200mg
of calcium daily  is related to a significant reduction in fracture
rate in the elderly.
Prolapse and Stress Incontinence
As postmenopausal women continue to outlive men they
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tend to become a greater proportion of all medical health
consumers and their health, both in terms of prevention and in
treatment will be the focus of future research.
Millions of women have genital prolapse, with or without
stress incontinence, and this greatly influences their quality of
life. A recent study reviewed  asymptomatic women and
assessed  prolapse/descent as measured from the hymen or
below. Subjects underwent a Pelvic Organ Prolapse
Quantification examination during a maximal Valsalva
maneouvre and in addition completed a questionnaire.
Hormone therapy was not associated with prolapse (P =0.9).
On multivariable analysis, less education (odds ratio [OR] 2.16,
95% CI 1.10-4.24) and higher vaginal parity (OR 1.61, 95% CI
1.03-2.50) were associated with prolapse at the level of the
hymen. For prolapse defined by the leading edge at or below
the hymen, older age had a decreased risk (OR 0.50, 95% CI
0.27-0.92) and less education, and larger babies had an
increased risk (OR 2.38, 95% CI 1.31-4.32 and OR 1.97, 95% CI
1.07-3.64, respectively).  Some degree of prolapse is found in
over 25% in older women of 70 years of age. Minor degrees of
uterine and vaginal wall prolapse is so common as to be regarded
as normal in the elderly.18
At present the most successful surgical intervention for
stress incontinence is the tension free tape (TVT). A cure rate
from stress incontinence of over 85 % has been quoted in various
prospective studies.
Another recent advance in the medical treatment of urinary
stress incontinence is duloxetine, targeting increased urethral
tone in response to raised intra-abdominal pressure. It is a
balanced serotonin re-uptake inhibitor which has been found
to be helpful in mild to moderate stress incontinence. In a study
utilising duloxetine, severe sufferers were noted to have urethral
hypermobility plus intrinsic sphincter deficiency with scarring,
fibrosis or fixity. Duloxetine efficacy was demonstrated even in
women with or without sphincter deficiency and women noted
improvement within two weeks of starting treatment: this was
maintained for the whole eight weeks of the trial period. Side
effects were common but these were usually transient and
subsided with time. Quality of life was improved to such an
extent that 20% of women initially booked for surgery were
reconsidering their choice of treatment.19
Human Papilloma Virus (HPV)
and cervical cancer
A conservative estimate indicates that worldwide, a quarter
of a million women die each year from cervical cancer and where
resources are scarce, and cytological screening is not readily
available, this carcinoma is still common.
The causal role of HPV types 16 and 18 has been clearly
established, with highly sensitive PCR techniques
demonstrating HPV DNA in 100% of histologically confirmed
cervical cancers. Persistent infection is the chronic complication,
especially with types 16 and 18, and monovalent vaccine testing
appears effective.
A cohort of women was followed for around 17.4 months
after completing the vaccination regimen. The incidence of
persistent HPV-16 infection was 3.8 per 100 woman-years at
risk in the placebo group and 0 per 100 woman-years at risk in
the vaccine group (100 % efficacy; 95 % CI, 90 to 100; P<0.001).
All nine cases of HPV-16–related cervical intraepithelial
neoplasia occurred among the placebo recipients.
Administration of this HPV-16 vaccine appears to reduce the
incidence of both HPV-16 infection and HPV-16–related cervical
intraepithelial neoplasia.20
The extensive bivalent trials by Harper et al  look even more
interesting.21 Women were vaccinated against the most common
oncogenic human papillomavirus (HPV) types, HPV-16 and
HPV-18.  A randomised, double-blind, controlled trial was
designed to assess the efficacy, safety, and immunogenicity of a
bivalent HPV-16/18 L1 virus-like particle vaccine for the
prevention of incident and persistent infection with these two
virus types, associated with cervical cytological abnormalities,
and precancerous lesions.  The study involved 1113 women aged
between 15-25 years of age, randomised to receive three doses
of the vaccine formulated.  In the according-to-protocol
analyses, vaccine efficacy was 91.6% (95% CI 64.5-98.0) against
incident infection and 100% against persistent infection (47.0-
100) with HPV-16/18. In the intention-to-treat analyses, vaccine
efficacy was 95.1% (63.5-99.3) against persistent cervical
infection with HPV-16/18 and 92.9% (70.0-98.3) against
cytological abnormalities associated with HPV-16/18 infection.
The vaccine was generally safe, well tolerated, and highly
immunogenic. The bivalent HPV vaccine was efficacious in
prevention of incident and persistent cervical infections with
HPV-16 and HPV-18, and associated cytological abnormalities
and lesions.  It has been postulated that vaccination against
HPV-16 and HPV-18 could substantially reduce incidence of
cervical cancer by up to 70%.
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